D. Boral Capital Reaffirms "Buy" Rating for Coya Therapeutics (NASDAQ:COYA)

Key Points

• D. Boral Capital has reaffirmed a "buy" rating for Coya Therapeutics (NASDAQ:COYA) with a target price of $18.00, indicating a potential upside of 192.64% from its previous close.
• Despite the positive ratings from several research firms, Coya's stock reported disappointing earnings, with an EPS loss of ($0.36) missing analyst estimates by ($0.14).
• Institutional investors are showing increased interest in Coya Therapeutics, with 39.75% of the company's stock now owned by hedge funds and other institutions.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating restated by investment analysts at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $18.00 target price on the stock. D. Boral Capital's price target points to a potential upside of 199.50% from the stock's current price.

Several other equities research analysts also recently commented on the stock. Chardan Capital reiterated a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, August 13th. Wall Street Zen cut Coya Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Lake Street Capital began coverage on Coya Therapeutics in a report on Wednesday, July 9th. They issued a "buy" rating and a $16.00 price objective on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, June 9th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $16.50.

Coya Therapeutics Stock Down 2.3%

COYA stock traded down $0.14 during trading on Wednesday, hitting $6.01. The company had a trading volume of 24,599 shares, compared to its average volume of 73,576. Coya Therapeutics has a 52-week low of $4.65 and a 52-week high of $10.24. The company has a 50 day simple moving average of $5.97 and a 200-day simple moving average of $6.09. The firm has a market capitalization of $100.55 million, a P/E ratio of -4.85 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The firm had revenue of $0.16 million during the quarter, compared to analysts' expectations of $0.78 million. Sell-side analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Coya Therapeutics during the second quarter worth approximately $119,000. Jane Street Group LLC boosted its holdings in Coya Therapeutics by 101.7% in the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock valued at $169,000 after purchasing an additional 13,176 shares in the last quarter. Charles Schwab Investment Management Inc. purchased a new position in shares of Coya Therapeutics during the 1st quarter worth approximately $65,000. CM Management LLC lifted its holdings in shares of Coya Therapeutics by 25.0% in the 1st quarter. CM Management LLC now owns 200,000 shares of the company's stock valued at $1,294,000 after buying an additional 40,000 shares during the period. Finally, Dauntless Investment Group LLC acquired a new position in shares of Coya Therapeutics during the 1st quarter worth $1,083,000. Institutional investors and hedge funds own 39.75% of the company's stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.